Zeltiq Aesthetics is a technology company.
Zeltiq Aesthetics has raised $50.0M across 2 funding rounds.
Zeltiq Aesthetics has raised $50.0M in total across 2 funding rounds.
Zeltiq Aesthetics has raised $50.0M in total across 2 funding rounds.
Zeltiq Aesthetics's investors include Aisling Capital, SV Health Investors, Venrock.
Zeltiq Aesthetics is a medical technology company, now a subsidiary of AbbVie based in Pleasanton, California, that develops and commercializes devices for cryolipolysis—a non-invasive fat reduction procedure branded as CoolSculpting. It targets pinchable fat deposits on areas like the abdomen, flanks, thighs, arms, and chin, serving dermatologists, plastic surgeons, aesthetic practitioners, and patients seeking body contouring without surgery.[1][4][5] The technology solves the problem of localized fat reduction through controlled cooling that triggers fat cell apoptosis (cell death) while sparing surrounding tissue, with millions of treatments performed globally by 2017.[2][3] Zeltiq went public in 2011 after raising $75 million, achieved market leadership in cryolipolysis by 2014, and demonstrated strong growth, reaching 2 million treatment cycles and 150,000 treatments by early 2012.[1][3]
Zeltiq Aesthetics was founded in 2005 as Juniper Medical, Inc. by Mitch Levinson, who previously led Thermage, a pioneer in radio frequency skin tightening devices.[1] The idea emerged from developing cryolipolysis, a process using extreme cold to selectively freeze and destroy fat cells ("selective cryolysis"), branded as CoolSculpting.[1][4] Renamed Zeltiq in July 2007, it gained FDA clearance in 2010 via the de novo pathway initially for skin numbing before dermatology procedures, though off-label body-sculpting use quickly spread through physician advocacy.[1] Pivotal moments included market entry for fat reduction, a 2014 FDA-cleared device update for thighs without suction, and rapid adoption—150,000 treatments by 2012—leading to its 2011 IPO.[1]
Zeltiq rides the wave of the non-invasive body contouring trend within the $4 billion global aesthetics market, driven by demand for minimally disruptive fat reduction amid rising obesity and cosmetic procedure popularity.[2] Timing was ideal post-2000s medtech boom in energy-based devices (e.g., Thermage roots), with FDA's de novo pathway enabling faster clearance for novel tech like cryolipolysis.[1] Favorable forces include aging populations, social media-fueled aesthetics growth, and physician adoption via off-label buzz turning into standard practice.[1][2] As part of AbbVie (post-2017 Allergan $2.48B acquisition, then AbbVie's 2020 $63B Allergan buy), it influences the ecosystem by bolstering integrated aesthetics portfolios, enabling cross-selling to practitioners and advancing regenerative medtech standards.[1][2]
Under AbbVie, Zeltiq's CoolSculpting platform is poised for expanded iterations, like advanced applicators or AI-enhanced precision, capitalizing on sustained aesthetics demand. Trends like personalized medtech, combination therapies (e.g., with injectables), and emerging markets will propel growth, potentially evolving its influence toward holistic body transformation ecosystems. This cements Zeltiq's legacy from scrappy innovator to cornerstone of non-surgical fat tech, transforming patient options in a booming field.[1][2][4]
Zeltiq Aesthetics has raised $50.0M across 2 funding rounds. Most recently, it raised $25.0M Series D in June 2010.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2010 | $25.0M Series D | Aisling Capital, SV Health Investors, Venrock | |
| Jul 1, 2008 | $25.0M Series C | Venrock |